mRNA Cancer Vaccine Collaboration and License Agreement by and betweenVaccine Collaboration and License Agreement • June 15th, 2020 • New York
KRAS is one of the most frequently mutated oncogenes in human cancer, occurring in approximately 30 percent of certain cancer types. KRAS mutations are found principally in non-small cell lung cancer (NSCLC), colorectal cancer and pancreatic cancer, and are associated with worse outcomes. Hotspots of KRAS mutations are found in different tumor types and can serve as tumor rejection epitopes. Presentation of these epitopes to the immune system may elicit an anti-tumor response. mRNA-5671 encodes for the four most commonly found KRAS mutations, and is designed to target most of the KRAS mutations that occur in NSCLC, colorectal cancer and pancreatic cancer.
Amended and Restated mRNA Cancer Vaccine Collaboration and License Agreement by and between MODERNATX, INC. and MERCK SHARP & DOHME CORP. April 17, 2018Vaccine Collaboration and License Agreement • November 9th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • New York
This Exhibit D to the Agreement covers financial planning, accounting policies and procedures to be followed in determining the Profit & Loss Share and the cost sharing between the Parties. The Profit & Loss Share shall be calculated on a Program-by-Program basis for a given Joint SAV Program or the PCV Program. The Profit & Loss Share is not a legal entity and has been defined for identification purposes only.
Amended and Restated mRNA Cancer Vaccine Collaboration and License Agreement by and between MODERNATX, INC. and MERCK SHARP & DOHME CORP. April 17, 2018Vaccine Collaboration and License Agreement • August 30th, 2018 • Moderna, Inc. • Biological products, (no disgnostic substances) • New York
This Exhibit D to the Agreement covers financial planning, accounting policies and procedures to be followed in determining the Profit & Loss Share and the cost sharing between the Parties. The Profit & Loss Share shall be calculated on a Program-by-Program basis for a given Joint SAV Program or the PCV Program. The Profit & Loss Share is not a legal entity and has been defined for identification purposes only.
